Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...
Recent popularity of JAK inhibitors in atopic dermatitis
The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...